ArticleJournal of controlled release : official journal of the Controlled Release Society2010
Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 114 citations in OpenAlex.
- Trial
- Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.PLoS medicine · 2020Trial
- Enhancing vaccine stability in transdermal microneedle platforms.Drug delivery and translational research · 2025Review
- Microneedle delivery systems for vaccines and immunotherapy.Smart molecules : open access · 2025Review
- Novel stereo DIC characterisation of microneedle and hypodermic needle insertion.Frontiers in bioengineering and biotechnology · 2025Article
- Current Status of Microneedle Array Technology for Therapeutic Delivery: From Bench to Clinic.Molecular biotechnology · 2024Review
- Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.Advanced drug delivery reviews · 2024Review
- Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective.Drug delivery and translational research · 2022Review
- Vaccine and vaccination as a part of human life: In view of COVID-19.Biotechnology journal · 2022Review
- Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial.NPJ vaccines · 2021Article
- Microarray patches enable the development of skin-targeted vaccines against COVID-19.Advanced drug delivery reviews · 2021Review
- Progress in microneedle array patch (MAP) for vaccine delivery.Human vaccines & immunotherapeutics · 2021Article
- Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.EBioMedicine · 2020Article
- The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization.Expert review of vaccines · 2020Review
- Microneedle-based intradermal delivery of stabilized dengue virus.Bioengineering & translational medicine · 2019Article
- Technology update: dissolvable microneedle patches for vaccine delivery.Medical devices (Auckland, N.Z.) · 2019Article
- Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice.Scientific reports · 2018Article
- Article
- The success of microneedle-mediated vaccine delivery into skin.Human vaccines & immunotherapeutics · 2016Review
- Microneedle patches for vaccination in developing countries.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
To address the limitations of conventional influenza vaccine manufacturing and delivery, this study investigated administration of virus-like particle (VLP) influenza vaccine using a microneedle patch. The goal was to determine if skin immunization with influenza VLP vaccine using microneedles enables dose sparing. We found that low-dose influenza (A/PR/8/34 H1N1) VLP vaccination using microneedles was more immunogenic than low-dose intramuscular (IM) vaccination and similarly immunogenic as high-dose IM vaccination in a mouse model. With a 1μg dose of vaccine, both routes showed similar immune responses and protective efficacy, with microneedle vaccination being more effective in inducing recall antibody responses in lungs and antibody secreting cells in bone marrow. With a low dose of vaccine (0.3μg), microneedle vaccination induced significantly superior protective immunity, which included binding and functional antibodies as well as complete protection against a high dose lethal infection with A/PR/8/34 virus, whereas IM immunization provided only partial (40%) protection. Therefore, this study demonstrates that microneedle vaccination in the skin confers more effective protective immunity at a lower dose, thus providing vaccine dose-sparing effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.